The NULEXA™ system (formerly known as the VELO System under LEX Diagnostics) redefines point-of-care diagnostics by combining ultra-fast speed and high sensitivity in a PCR-based molecular system.
This breakthrough multiplex molecular diagnostics platform is the first to deliver true RT-PCR influenza A/B + SARS results in less than 10 minutes, directly from a swab sample.* The NULEXA System is CLIA waived and features proprietary technology and a cartridge-based design that eliminates the need for external liquid handling, delivering the speed, reliability and ease of use that fits seamlessly into busy point-of-care workflows.
Highly accurate and streamlined workflow
True real-time PCR results are delivered using proprietary thermal cycling technology and a cartridge-based design that eliminates the need for external liquid handling.
With results available in less than 10 minutes, treatment decisions can be made during the patient’s visit, which helps improve the patient experience and minimizes loss to follow-up care.
The NULEXA™ System is CLIA waived and requires only one minute of hands-on time. With 3 simple steps to results and an easy-to-use workflow, staff can focus more on patient care.
*As of June 16, 2026, based on date of FDA clearance and time to result for RT-PCR Influenza A/B + SARS-CoV-2 diagnostic tests for point-of-care settings. See QuidelOrtho webpage
